Capsugel ICSE/CPHI Booth #8F06
Expanded Finished Product Manufacturing Facilities Ready for Increased Licaps® Production
MORRISTOWN, NJ and BORNEM, BELGIUM, October 11, 2012 – A global surveyi of decision-makers in the pharmaceutical industry published this week reveals a technology void in innovative dosage solutions. There is a clear need for innovative delivery technologies that ensure product integrity, increased bioavailability and reduced production-to-market lead time. Capsugel’s novel Fusion Technology for its Licaps capsules aims to fill this gap and set a new standard for liquid and semi-solid lipid based capsules by providing a dosage solution that can be used to meet the needs across a spectrum of challenging compounds. The company showcased its Licaps Fusion Technology this week at ICSE/CPHI 2012 taking place in Madrid.
“We continuously make innovations in our technologies so that we find new and better ways to help customers deliver effective, high quality products,” said Keith Hutchison, PhD, Senior Vice President of R&D at Capsugel. “Our improved Licaps Fusion Technology has been applied to products which received regulatory approval for use in clinical trials as well as products that are now commercially available. Our technology continues to exceed customer expectations.”
The recent completion of Capsugel’s state-of-the-art pharmaceutical manufacturing facility in the United States makes available additional capacity for the production of Licaps products, adding to existing sites in France and Japan to meet customer needs. The Licaps product manufacturing facility in Greenwood, SC now meets ISO 8 clean room environment standards and its quality systems support all cGMP requirements.
HOW IT WORKS
The Licaps Fusion Technology ensures that the two pieces of the capsules are hermetically sealed together, resulting in a perfectly tight, one-piece capsule. Licaps capsules are gelatin or HPMC hard capsules exclusively designed to optimize liquid filling and sealing.
ABOUT CAPSUGEL Capsugel is a global leader in innovative dosage forms and solutions for the healthcare industry. Offering a comprehensive array of products and services, from hard gelatin, liquid-filled, and vegetarian capsules, to innovative R&D product development services, Capsugel is at the forefront of drug delivery innovation providing support to customers from formulation to final production. For more information about Capsugel, visit www.capsugel.com.
For media inquiries, contact Catherine Lehmann, Marketing Manager at +33 3 89 20 58 46 or Alyssa Augustine, Director of Communications at +1 860 389 0868. Global Industry Survey, Nice Insights 2012
Related News
-
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News Women in Pharma: Advocating for trans healthcare in pharma
In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance